Table 2.
Units of PCC administered per patient, and resultant change in administration of blood products
| Indication | Mean dose per patient (IU [range]) | Post-PCC changea in administration of: | |||
| FFP | Red blood cells | Cryoprecipitate | Platelets | ||
| Cardiac surgery (CABG; n = 5) | 1,500 (500–4,000) | -15.8% | -63.5% | -50.0% | 20.0% |
| Cardiac surgery (valve replacement; n = 2) | 500 (500 to 500) | -21.1% | -83.3% | -40.0% | -66.7% |
| Other surgery (n = 9) | 850 (500 to 2,000) | -25.9% | -60.3% | -84.0% | -29.4% |
| Warfarin reversal (n = 8) | 1,800 (1,000 to 4,000) | -50.0% | N/A | N/A | N/A |
| All patients (n = 24) | 1,250 (500 to 4,000) | -22.7% | -63.9% | -70.5% | -22.2% |
The dose is given as IU of factor IX, assuming that each PCC vial provides 500 IU. aThe percentage change was calculated by dividing the quantity of blood product administered during the 24 hours after PCC administration, by the quantity administered during the 24 hours before PCC administration; a negative value indicates a decrease after PCC administration. CABG, coronary artery bypass graft; FFP, fresh frozen plasma; N/A, not available; PCC, prothrombin complex concentrate.